Immune checkpoint inhibitors have revolutionized the field of oncology, providing an effective treatment option for several oncology indications.
To date, seven immune checkpoint inhibitors have received regulatory approval: one CTLA-4 inhibitor and six PD-1/PD-L1 inhibitors.
While only approximately 20% of cancer patients will respond to these treatments, the introduction of these agents to the market has vastly improved prognosis for some patients. These agents are quickly becoming the new standard of care for many malignancies, but their limited response rates are driving a surge in both preclinical and clinical research into novel immunotherapy options.
By building on the success of the established agents and evaluating alternative targets (other than PD-1/PD-L1 or CTLA-4) and mechanisms of action, a new generation of immune checkpoint agents have the potential to further impact the oncology treatment algorithm.
In this eBook, DRG Oncology expert Ann-Marie Looney shares her perspective on emerging therapies and trends shaping the future of the checkpoint inhibitors landscape.
Key topics covered include: